The Role of the N-terminal Segment of CCR5 in HIV-1 Env-mediated Membrane Fusion and the Mechanism of Virus Adaptation to CCR5 Lacking This Segment
Overview
Affiliations
Background: HIV-1 envelope glycoprotein (Env) induces membrane fusion as a result of sequential binding to CD4 and chemokine receptors (CCR5 or CXCR4). The critical determinants of CCR5 coreceptor function are the N-terminal domain (Nt) and the second extracellular loop. However, mutations in gp120 adapt HIV-1 to grow on cells expressing the N-terminally truncated CCR5(Delta 18) (Platt et al., J. Virol. 2005, 79: 4357-68).
Results: We have functionally characterized the adapted Env (designated Env(NYP)) using a quantitative cell-cell fusion assay. The rate of fusion with target cells expressing wild-type CCR5 and the resistance to fusion inhibitors was virtually identical for wild-type Env and Env(NYP), implying that the coreceptor affinity had not increased as a result of adaptation. In contrast, Env(NYP)-induced fusion with cells expressing CCR5(Delta 18) occurred at a slower rate and was extremely sensitive to the CCR5 binding inhibitor, Sch-C. Resistance to Sch-C drastically increased after pre-incubation of Env(NYP)- and CCR5(Delta 18)-expressing cells at a temperature that was not permissive to fusion. This indicates that ternary Env(NYP)-CD4-CCR5(Delta 18) complexes accumulate at sub-threshold temperature and that low-affinity interactions with the truncated coreceptor are sufficient for triggering conformational changes in the gp41 of Env(NYP) but not in wild-type Env. We also demonstrated that the ability of CCR5(Delta 18) to support fusion and infection mediated by wild-type Env can be partially reconstituted in the presence of a synthetic sulfated peptide corresponding to the CCR5 Nt. Pre-incubation of wild-type Env- and CCR5(Delta 18)-expressing cells with the sulfated peptide at sub-threshold temperature markedly increased the efficiency of fusion.
Conclusion: We propose that, upon binding the Nt region of CCR5, wild-type Env acquires the ability to productively engage the extracellular loop(s) of CCR5 - an event that triggers gp41 refolding and membrane merger. The adaptive mutations in Env(NYP) enable it to more readily release its hold on gp41, even when it interacts weakly with a severely damaged coreceptor in the absence of the sulfopeptide.
Novel small synthetic HIV-1 V3 crown variants: CCR5 targeting ligands.
Anitha A, Narayanan P, Ajayakumar N, Sivakumar K, Kumar K J Biochem. 2022; 172(3):149-164.
PMID: 35708645 PMC: 9445593. DOI: 10.1093/jb/mvac052.
Schapiro H, Khasnis M, Ahn K, Karagiaridi A, Hayden S, Cilento M PLoS Pathog. 2022; 18(5):e1010531.
PMID: 35584191 PMC: 9154124. DOI: 10.1371/journal.ppat.1010531.
Zhang S, Holmes A, Dick A, Rashad A, Enriquez Rodriguez L, Canziani G Retrovirology. 2021; 18(1):31.
PMID: 34627310 PMC: 8501640. DOI: 10.1186/s12977-021-00575-z.
Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.
Ahn K, Root M J Biol Chem. 2017; 292(40):16498-16510.
PMID: 28696261 PMC: 5633110. DOI: 10.1074/jbc.M117.791731.
Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.
Khasnis M, Halkidis K, Bhardwaj A, Root M PLoS Pathog. 2016; 12(12):e1006098.
PMID: 27992602 PMC: 5222517. DOI: 10.1371/journal.ppat.1006098.